Wɔfa akwan pii so na wohu sɛ obi anya Alzheimer yare no, ebi ne sɛ wɔbɛhwehwɛ no yiye, wɔbɛsɔ no ahwɛ ahu nea ɛhaw no, na wɔasan ahwɛ ne amemene mu, na wɔayi nneɛma foforo a ebetumi ama wanya yare no afi hɔ.
1. Aduruyɛ mu nhwehwɛmu: Oduruyɛfo bɛhwɛ wo nipadua mu na wakyerɛw yare a woanya ho nsɛm pii de ahu nea ebetumi ama wo werɛ afi ade anaa woadi dɛm, te sɛ atiridii, aduannuru a enni wo nipadua mu, anaa amemene mu kokoram.
2. Adwene ne amemene mu nhwehwɛmu: Saa nhwehwɛmu yi hwehwɛ sɛnea obi tumi kae ade, kasa, sɛnea otumi di ɔhaw ho dwuma, ne adwene mu nneɛma foforo mu de hu adwene mu haw no kɛse ne nsonsonoe a ɛda adwene a ɛyera a efi onyin mu ne adwenemhaw mu.
3. Amemene mu mfonini: Magnetic resonance imaging (MRI) anaa computed tomography (CT) scans betumi aboa ma wɔahu nsakrae a ɛwɔ amemene no mu a ebetumi akyerɛ sɛ obi anya Alzheimer yare.
Wotumi de positron emission tomography (PET) nso hwɛ sɛnea protein ahorow bi a ɛka Alzheimer yare no ho dodow te.
4. Mogya mu nhwehwɛmu: Nhwehwɛmu a wɔayɛ nnansa yi ada no adi sɛ mogya mu nhwehwɛmu bi betumi aboa ma wɔahu Alzheimer yare no denam protein anaa nneɛma bi a ɛma wohu yare no dodow a wobesusuw so.
5. Nea ɛsɛ sɛ wɔhwehwɛ mu hu: Esiane sɛ wonnya nnipakan bi a wɔde hu Alzheimer yare no nti, mpɛn pii no, nea ɛma wohu sɛ obi anya yare no ne sɛ wɔbɛhwehwɛ mu ahu nneɛma foforo a ebetumi ama wanya adwenemhaw.
Ɛho hia sɛ yɛhyɛ no nsow sɛ sɛ obi wu a, ɛdenam amemene mu nneɛma a wobehu so nkutoo na wobetumi ahu sɛ ɔwɔ Alzheimer yare.
Nanso, nhwehwɛmu a wɔyɛ nnɛ no betumi ama obi anya yare no ho nimdeɛ pii bere a onii no da so te ase no.
Sɛ obi nya yare no bi ntɛm a, ɛboa ma otumi fi ase sa no yare na ɔyɛ nhyehyɛe ma daakye.
Liu SS, Zhu SQ: [Correlation between Alzheimer disease and cataract]. Zhonghua Yan Ke Za Zhi. 2017, 53 (4): 314-316.
Gauthier S: Practical guidelines for the antemortem diagnosis of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry. 1985, 9 (5-6): 491-5.
Rubin R: New Test to Help Diagnose Alzheimer Disease. JAMA. 2022, 327 (23): 2281.
[Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia]. Fortschr Neurol Psychiatr. 2022, 90 (7-08): 326-335.
Kapp MB: Physicians' legal duties regarding the use of genetic tests to predict and diagnose Alzheimer disease. J Leg Med. 2000, 21 (4): 445-75.
Britschgi M, Wyss-Coray T: Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol. 2009, 66 (2): 161-5.
Volicer L, Berman SA, Cipolloni PB, Mandell A: Persistent vegetative state in Alzheimer disease. Does it exist? Arch Neurol. 1997, 54 (11): 1382-4.
Imabayashi E, Saitoh Y, Tsukamoto T, Sakata M, Takano H: Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18 F-THK5351. Clin Nucl Med. 2022, 47 (12): 1066-1068.
Martínez A, Lahiri DK, Giacobini E, Greig NH: Advances in Alzheimer therapy: understanding pharmacological approaches to the disease. Curr Alzheimer Res. 2009, 6 (2): 83-5.
['Nsɛm a Ɛnsɛ sɛ Wɔka:']
['Wɔayɛ wɛbsaet yi sɛ wɔmfa nkyerɛkyerɛ na wɔmfa nkyerɛkyerɛ afoforo, na ɛnyɛ sɛ wɔde rema aduruyɛ ho afotu anaa wɔde rema adwuma.']
['Ɛnsɛ sɛ wɔde nsɛm a wɔde ama no di dwuma de hwehwɛ yare bi ho yare anaa wɔde sa yare, na ɛsɛ sɛ wɔn a wɔrehwehwɛ ayaresa ho afotu no kohu oduruyɛfo a ɔwɔ tumi krataa.']
['Yɛsrɛ wo hyɛ no nsow sɛ, sɛnea wɔhwɛ nsɛmmisa no so no, sɛ ɛba sɛ wɔrekyerɛw nnipa dodow a wɔanya yare bi ho asɛm a, ɛntaa nsi yiye.']
['Hwehwɛ afotu fi wo duruyɛfo anaa ɔyaresafo foforo a ɔfata hɔ bere biara wɔ yare bi ho. Nnya adwene sɛ wo nsa bɛka oduruyɛfo afotu anaasɛ wubetwa so esiane biribi a woakenkan wɔ wɛbsaet yi so nti. Sɛ wususuw sɛ ebia wo ho behia wo wɔ ayaresa mu a, frɛ 911 anaa kɔ ayaresabea a ɛbɛn wo paa ntɛm ara.']
['Nsɛm a wɔmmɔ ho ban:']
['Digital Millennium Copyright Act a wɔhyɛe wɔ afe 1998 mu, 17 U.S.C. § 512 (DMCA) no ma wɔn a wɔwɔ hokwan sɛ wɔyɛ wɔn nneɛma no kwan sɛ wɔyɛ nea wɔpɛ biara.']
["Sɛ wugye di sɛ nsɛm anaa nneɛma a ɛwɔ yɛn wɛbsaet anaa yɛn dwumadibea no mu bi to wo mmara a wode bɔɔ nneɛma ho ban no a, wo (anaa w'ananmusifo) betumi de krataa akɔma yɛn de aka sɛ yɛnyi nsɛm anaa nneɛma no, anaa yɛmmɔ kwan mma wonnya bi."]
["Ɛsɛ sɛ wɔde krataa ne email na ɛbɔ amanneɛ (hwɛ 'Contact' afã hɔ na wubehu email address)."]
['DMCA hwehwɛ sɛ wo amanneɛbɔ a ɛfa nea wɔkyerɛ sɛ ɛyɛ mmara a wobu so ho no de nsɛm a edidi so yi ka ho: (1) adwuma a mmara bɔ ho ban a wɔkyerɛ sɛ wɔadi so no ho asɛm; (2) nsɛm a wɔkyerɛ sɛ wɔadi so no ho asɛm ne nsɛm a ɛbɛboa yɛn ma yɛahu baabi a ɛwɔ; (3) wo ho nsɛm a yɛde bedi nkitaho, a wo address, telefon nɔma ne email address ka ho; (4) wo nsɛm a ɛkyerɛ sɛ wugye di sɛ nea wɔabɔ ho sobo no nyɛ nea mmara ma ho kwan; ']
['(5) wo nsahyɛ a ɛkyerɛ sɛ nsɛm a ɛwɔ amanneɛbɔ no mu yɛ nokware, na wowɔ tumi sɛ wode nea wɔkyerɛ sɛ woadi ho dwuma no bedi dwuma; ']
['ne (6) nea ɔwɔ tumi sɛ ɔyɛ biribi ma obi a ɔwɔ tumi sɛ ɔyɛ biribi ma no no nsaano nkyerɛwee.']
['Sɛ woamfa nsɛm a yɛaka yi nyinaa anka ho a, ebetumi ama wo ka no akyɛ.']
['Nkitahodi']
['Yɛsrɛ wo, fa nsɛmmisa anaa nyansahyɛ biara a wowɔ brɛ yɛn wɔ e-mail so.']
How is alzheimer diagnosed?
Alzheimer's disease is diagnosed through a combination of methods, including a thorough medical evaluation, cognitive and neuropsychological tests, brain imaging, and the process of elimination of other possible causes.
1. Medical evaluation: A doctor will perform a physical examination and take a detailed medical history to rule out other possible causes of memory loss or cognitive decline, such as thyroid problems, vitamin deficiencies, or brain tumors.
2. Cognitive and neuropsychological tests: These tests assess memory, language, problem-solving, and other cognitive functions to determine the extent of cognitive impairment and to differentiate between normal age-related memory loss and dementia.
3. Brain imaging: Magnetic resonance imaging (MRI) or computed tomography (CT) scans can help identify structural changes in the brain that may indicate Alzheimer's disease.
Positron emission tomography (PET) scans can also be used to measure the levels of certain proteins associated with Alzheimer's disease.
4. Blood tests: Recent research has shown that certain blood tests can help diagnose Alzheimer's disease by measuring the levels of specific proteins or biomarkers associated with the disease.
5. Process of elimination: Since there is no single definitive test for Alzheimer's disease, diagnosis often involves ruling out other possible causes of dementia-like symptoms.
It is important to note that a definitive diagnosis of Alzheimer's disease can only be made after death through an examination of brain tissue.
However, current diagnostic methods can provide a high level of certainty for a clinical diagnosis while the person is still alive.
Early diagnosis is important for starting treatment and planning for the future.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɛfa ho']
['BioMedLib de kɔmputa a wɔde di dwuma (mfidie a wɔde sua ade) na ɛma nsɛmmisa ne mmuae.']
['Yɛde nhoma ahorow a ɛfa nnuruyɛ mu ɔpepem 35 a ɛwɔ PubMed/Medline ne RefinedWeb mu na efii ase.']
